Ascendis Pharma A/S

SecurityASND / Ascendis Pharma A/S
InstitutionBarclays Plc
Latest Disclosed Ownership11,244 shares
Latest Disclosed Value $ 2,397,671
Barclays Plc ownership in ASND / Ascendis Pharma A/S

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 11,244 shares of Ascendis Pharma A/S (US:ASND) valued at $2,397,671 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 10,782 shares of Ascendis Pharma A/S. This represents a change in shares of 4.28% during the quarter. The current value of the position is $2,437,587 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (ASND) in the form of stock options. The firm currently holds call options representing 100 of underlying shares valued at $21,324 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ASND / Ascendis Pharma A/S Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A ADR 04351P101 11,244 462 4.28 2,398 11.85 0.0006
2026-03-31 2025-09-30 13F/A-3 ASCENDIS PHARMA A ADR 04351P101 10,782 -1,147 -9.62 2,144 4.13 0.0005
2026-03-19 2025-09-30 13F/A-2 ASCENDIS PHARMA A ADR 04351P101 18,736 6,807 2,797 0.0007
2025-11-12 2025-09-30 13F ASCENDIS PHARMA A ADR 04351P101 10,782 -1,147 2,144 0.0005
2026-02-27 2025-06-30 13F/A-2 ASCENDIS PHARMA A ADR 04351P101 11,929 1,539 14.81 2,059 27.12 0.0005
2025-08-14 2025-06-30 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 11,929 1,539 2 0.0005
2025-08-13 2025-06-30 13F ASCENDIS PHARMA A ADR 04351P101 11,929 1,539 2 0.0002
2026-03-17 2025-03-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 10,390 -18,586 -64.14 1,619 -59.41 0.0005
2025-05-15 2025-03-31 13F ASCENDIS PHARMA A ADR 04351P101 10,390 -18,586 2 0.0005
2026-03-19 2024-12-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 28,976 10,240 54.65 3,989 42.62 0.0011
2025-02-13 2024-12-31 13F ASCENDIS PHARMA A ADR 04351P101 28,976 10,240 4 0.0011
2026-03-31 2024-09-30 13F/A-2 ASCENDIS PHARMA A ADR 04351P101 18,736 -268 -1.41 2,797 7.95 0.0007
2024-11-19 2024-09-30 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 18,736 -268 3 0.0007
2024-11-15 2024-09-30 13F ASCENDIS PHARMA A ADR 04351P101 18,736 -268 3 0.0002
2026-03-23 2024-06-30 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 19,004 -2,068 -9.81 2,592 -18.65 0.0008
2024-08-14 2024-06-30 13F ASCENDIS PHARMA A ADR 04351P101 19,004 -2,068 3 0.0008
2026-03-24 2024-03-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 21,072 3,747 21.63 3,185 45.97 0.0011
2024-05-15 2024-03-31 13F ASCENDIS PHARMA A ADR 04351P101 21,072 3,747 3 0.0011
2026-03-25 2023-12-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 17,325 -157 -0.90 2,182 33.29 0.0008
2024-02-15 2023-12-31 13F ASCENDIS PHARMA A ADR 04351P101 17,325 -157 2 0.0008
2026-03-26 2023-09-30 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 17,482 16,874 2,775.33 1,637 2,931.48 0.0010
2023-11-07 2023-09-30 13F ASCENDIS PHARMA A ADR 04351P101 17,482 16,874 2 0.0010
2026-03-30 2023-06-30 13F/A-2 ASCENDIS PHARMA A ADR 04351P101 608 -68,294 -99.12 54 -99.27 0.0000
2023-09-20 2023-06-30 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 608 -68,294 0 0.0000
2023-08-03 2023-06-30 13F ASCENDIS PHARMA A ADR 04351P101 608 -68,294 0 0.0000
2026-03-30 2023-03-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 68,902 12,195 21.51 7,388 6.67 0.0034
2023-05-04 2023-03-31 13F ASCENDIS PHARMA A ADR 04351P101 68,902 12,195 7 0.0034
2026-03-30 2022-12-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 56,707 -68,114 -54.57 6,926 -46.27 0.0031
2023-02-13 2022-12-31 13F ASCENDIS PHARMA A ADR 04351P101 56,707 -68,114 7 0.0031
2022-11-03 2022-09-30 13F ASCENDIS PHARMA A ADR 04351P101 124,821 -20,223 -13.94 12,889 -4.41 0.0141
2022-08-12 2022-06-30 13F ASCENDIS PHARMA A ADR 04351P101 145,044 144,179 16,668.09 13,483 13,118.63 0.0082
2022-05-16 2022-03-31 13F ASCENDIS PHARMA A ADR 04351P101 865 238 37.96 102 21.43 0.0001
2022-02-23 2021-12-31 13F/A-1 ASCENDIS PHARMA A ADR 04351P101 627 -34,082 -98.19 84 -98.48 0.0000
2022-02-14 2021-12-31 13F ASCENDIS PHARMA A ADR 04351P101 627 -34,082 84 0.0000
2021-11-09 2021-09-30 13F ASCENDIS PHARMA A ADR 04351P101 34,709 34,024 4,967.01 5,532 6,046.67 0.0025
2021-08-13 2021-06-30 13F ASCENDIS PHARMA A ADR 04351P101 685 -3,354 -83.04 90 -82.69 0.0000
2021-05-13 2021-03-31 13F ASCENDIS PHARMA A ADR 04351P101 4,039 -298 -6.87 520 -28.08 0.0003
2021-02-11 2020-12-31 13F ASCENDIS PHARMA A ADR 04351P101 4,337 216 5.24 723 13.68 0.0004
2020-11-12 2020-09-30 13F ASCENDIS PHARMA A ADR 04351P101 4,121 138 3.46 636 7.98 0.0004
2020-08-12 2020-06-30 13F ASCENDIS PHARMA A S ADR 04351P101 3,983 3,654 1,110.64 589 1,491.89 0.0005
2020-05-13 2020-03-31 13F ASCENDIS PHARMA A S ADR 04351P101 329 -49 -12.96 37 -28.85 0.0000
2020-02-10 2019-12-31 13F ASCENDIS PHARMA A S ADR 04351P101 378 -8,233 -95.61 52 -93.73 0.0000
2019-11-15 2019-09-30 13F/A-1 ASCENDIS PHARMA A S ADR 04351P101 8,611 8,313 2,789.60 829 2,338.24 0.0005
2019-11-14 2019-09-30 13F ASCENDIS PHARMA A S ADR 04351P101 8,611 8,313 829 191.6657
2019-08-14 2019-06-30 13F ASCENDIS PHARMA A S ADR 04351P101 298 -9,313 -96.90 34 -96.99 0.0000
2019-05-15 2019-03-31 13F ASCENDIS PHARMA A S ADR 04351P101 9,611 -11,022 -53.42 1,131 -12.53 0.0008
2019-02-14 2018-12-31 13F ASCENDIS PHARMA A S ADR 04351P101 20,633 15,613 311.02 1,293 263.20 0.0010
2018-11-14 2018-09-30 13F ASCENDIS PHARMA A S ADR 04351P101 5,020 137 2.81 356 9.54 0.0002
2018-08-14 2018-06-30 13F ASCENDIS PHARMA A S ADR 04351P101 4,883 -377 -7.17 325 -5.80 0.0003
2018-05-15 2018-03-31 13F ASCENDIS PHARMA A S ADR 04351P101 5,260 560 11.91 345 83.51 0.0003
2018-02-14 2017-12-31 13F ASCENDIS PHARMA A S ADR 04351P101 4,700 -300 -6.00 188 3.87 0.0002
2017-11-14 2017-09-30 13F ASCENDIS PHARMA A S ADR 04351P101 5,000 5,000 181 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A OPT Call 100 21 n/a n/a n/a
2026-03-23 2024-06-30 13F/A ASCENDIS PHARMA A OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F ASCENDIS PHARMA A OPT Call 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A ASCENDIS PHARMA A OPT Call 119,720 432.09 18,098 538.83 n/a n/a n/a
2024-05-15 2024-03-31 13F ASCENDIS PHARMA A OPT Call 119,720 18 n/a n/a n/a
2026-03-25 2023-12-31 13F/A ASCENDIS PHARMA A OPT Call 22,500 2,834 n/a n/a n/a
2024-02-15 2023-12-31 13F ASCENDIS PHARMA A OPT Call 22,500 3 n/a n/a n/a
2019-08-14 2019-06-30 13F ASCENDIS PHARMA A S OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-15 2019-03-31 13F ASCENDIS PHARMA A S OPT Call 129,500 15,242 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-03-23 2024-06-30 13F/A ASCENDIS PHARMA A OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F ASCENDIS PHARMA A OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A ASCENDIS PHARMA A OPT Put 72,500 222.22 10,960 286.83 n/a n/a n/a
2024-05-15 2024-03-31 13F ASCENDIS PHARMA A OPT Put 72,500 11 n/a n/a n/a
2026-03-25 2023-12-31 13F/A ASCENDIS PHARMA A OPT Put 22,500 2,834 n/a n/a n/a
2024-02-15 2023-12-31 13F ASCENDIS PHARMA A OPT Put 22,500 3 n/a n/a n/a
2022-02-23 2021-12-31 13F/A ASCENDIS PHARMA A OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F ASCENDIS PHARMA A OPT Put 0 0 n/a n/a n/a
2021-11-09 2021-09-30 13F ASCENDIS PHARMA A OPT Put 38,300 6,105 n/a n/a n/a
2019-08-14 2019-06-30 13F ASCENDIS PHARMA A S OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-15 2019-03-31 13F ASCENDIS PHARMA A S OPT Put 67,000 75.85 7,886 230.37 n/a n/a n/a
2019-02-14 2018-12-31 13F ASCENDIS PHARMA A S OPT Put 38,100 2,387 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.